Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,530,362 papers from all fields of science
Search
Sign In
Create Free Account
albiglutide
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, with antihyperglycemic activity. Albiglutide is composed of a GLP-1 (7-36) dimer…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
0.5 ML albiglutide 60 MG/ML Pen Injector [Tanzeum]
Glucagon-Like Peptide 1
analogs & derivatives
Narrower (1)
Tanzeum
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes
S. Unni
,
E. Wittbrodt
,
+4 authors
C. McAdam-Marx
Diabetes, obesity and metabolism
2018
Corpus ID: 19394416
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare…
Expand
Review
2018
Review
2018
Albiglutide for the management of type 2 diabetes
M. Rendell
Expert Review of Endocrinology & Metabolism
2018
Corpus ID: 51889904
ABSTRACT Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and…
Expand
Review
2017
Review
2017
The safety of albiglutide for the treatment of type 2 diabetes
M. Rendell
Expert Opinion on Drug Safety
2017
Corpus ID: 40433730
ABSTRACT Introduction: Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection…
Expand
2016
2016
Lack of Benefit for Liraglutide in Heart Failure.
S. Carbone
,
R. Arena
,
A. Abbate
Journal of the American Medical Association (JAMA…
2016
Corpus ID: 40458675
2015
2015
Albiglutide does not impair the counter‐regulatory hormone response to hypoglycaemia: a randomized, double‐blind, placebo‐controlled, stepped glucose clamp study in subjects with type 2 diabetes…
M. Hompesch
,
A. Jones-Leone
,
+5 authors
R. Reinhardt
Diabetes, obesity and metabolism
2015
Corpus ID: 12673900
To determine if the glucagon‐like peptide‐1 (GLP‐1) receptor agonist albiglutide, once weekly, impairs counter‐regulatory…
Expand
2015
2015
DPP-4 inhibitors and risk of heart failure EXAMINEd
E. Standl
,
O. Schnell
The Lancet
2015
Corpus ID: 41654425
Review
2014
Review
2014
Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
B. Ahrén
World Journal of Diabetes
2014
Corpus ID: 21969235
There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl…
Expand
Review
2013
Review
2013
Medicinal chemistry of glucagon-like peptide receptor agonists.
L. Jones
,
David A. Price
Progress in Medicinal Chemistry
2013
Corpus ID: 205155171
2010
2010
Individualised incretin-based treatment for type 2 diabetes
M. Nauck
,
J. Meier
The Lancet
2010
Corpus ID: 31758367
Review
2009
Review
2009
Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.
G. Tomkin
Current opinion in molecular therapeutics (Print)
2009
Corpus ID: 37706903
Albiglutide, under development by GlaxoSmithKline plc for the treatment of type 2 diabetes mellitus (T2DM), is an albumin-fusion…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE